Alzheimer's-focused Aprinoia Therapeutics sets terms for $24M IPO

seekingalpha02-27

Aprinoia Therapeutics (APRI), which terminated a merger deal with Ross Acquisition Corp. II (ROSS) last August, has set terms for a proposed $24M US initial public offering. The biotech company said ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2414852798?lang=en_US&edition=fundamental","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1994989524/image_1994989524.jpg","is_english":true,"pubTime":"2024-02-27 04:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2414852798","market":"us","top_or_hot":-1,"title":"Alzheimer's-focused Aprinoia Therapeutics sets terms for $24M IPO","media":"seekingalpha","content":"<div>\n<p>Aprinoia Therapeutics (APRI), which terminated a merger deal with Ross Acquisition Corp. II (ROSS) last August, has set terms for a proposed $24M US initial public offering. The biotech company said ...</p>\n\n<a href=\"https://seekingalpha.com/news/4071844-alzheimers-focused-aprinoia-therapeutics-sets-terms-for-24m-ipo\">Source Link</a>\n\n</div>\n","source":"seekingalpha_hot_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Alzheimer's-focused Aprinoia Therapeutics sets terms for $24M IPO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAlzheimer's-focused Aprinoia Therapeutics sets terms for $24M IPO\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-02-27 04:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4071844-alzheimers-focused-aprinoia-therapeutics-sets-terms-for-24m-ipo><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Aprinoia Therapeutics (APRI), which terminated a merger deal with Ross Acquisition Corp. II (ROSS) last August, has set terms for a proposed $24M US initial public offering. The biotech company said ...</p>\n\n<a href=\"https://seekingalpha.com/news/4071844-alzheimers-focused-aprinoia-therapeutics-sets-terms-for-24m-ipo\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ROSS","symbol_name":"Ross Acquisition II Corp","start_time":0,"source_url":"https://seekingalpha.com/news/4071844-alzheimers-focused-aprinoia-therapeutics-sets-terms-for-24m-ipo","article_id":"2414852798","we_media_id":null,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1994989524/image_1994989524.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2414852798","pubTimestamp":1708979443,"sourceInfo":{"source_id":"seekingalpha_hot_news","name":"SeekingAlpha"},"weMediaInfo":null,"summary":"Aprinoia Therapeutics (APRI), which terminated a merger deal with Ross Acquisition Corp. II (ROSS) last August, has set terms for a proposed $24M US initial public offering. The biotech company said i","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"ROSS":"Ross Acquisition II Corp"},"translate_title":"专注于阿尔茨海默病的Aprinoia Therapeutics为2400万美元的首次公开募股设定条款","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ROSS":1},"content_text":"Aprinoia Therapeutics (APRI), which terminated a merger deal with Ross Acquisition Corp. II (ROSS) last August, has set terms for a proposed $24M US initial public offering. The biotech company said in an SEC filing that it is looking to offer 2M ordinary shares priced $10 to $14 per share, which would raise $24M if priced at the midpoint. Underwriters would be granted a 45-day option to buy up to 300K additional shares to cover over-allotments. Aprinoia hopes to list its shares on Nasdaq under the symbol APRL. US Tiger Securities is serving as lead bookrunner. Aprinoia first filed for the IPO in January. Based in Cambridge, Mass., Aprinoia is developing diagnostics and therapies for neurodegenerative diseases such as Alzheimer’s. The company’s lead product, APN-1607, is in Phase 3 testing as a PET diagnostic tracer for progressive supranuclear palsy, or PSP, and Alzheimer’s. The company also has a therapy candidate in Phase 1 development for the conditions. Last year, Aprinoia agreed to be acquired by Ross Acquisition II, which is backed by Wilbur Ross and Larry Kudlow. The deal was called off in August.   More on APRINOIA Therapeutics Inc.  Aprinoia Therapeutics Starts $50 Million IPO For Neurodegenerative Disease Treatments Financial information for APRINOIA Therapeutics Inc.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.28.3","shortVersion":"4.28.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2414852798"}